Pennsylvania, USA, November 18, 2026
INOVIO has submitted a Conditional Marketing Authorization (CMA) application to the European Medicines Agency (EMA) for VOCERYQ™ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd), previously known as INO-3107, for the treatment of adults with recurrent respiratory papillomatosis (RRP). The submission marks a significant regulatory milestone for the biotechnology company as it seeks to expand access to its investigational DNA-based immunotherapy in Europe. VOCERYQ is designed to reduce the frequency of surgical papilloma excisions in patients with RRP, a rare human papillomavirus (HPV)-associated disease that can cause recurrent growths in the respiratory tract, voice impairment, and potentially serious airway complications. The European application follows the product’s recent FDA accelerated approval in the United States, strengthening its regulatory progress in addressing a rare disease with substantial unmet treatment needs.
EMA Submission Supported by Clinical and Manufacturing Evidence
The Conditional Marketing Authorization application is supported by a comprehensive package of preclinical, clinical, and manufacturing data, including findings from INOVIO’s clinical studies published in Nature Communications and The Laryngoscope in 2025. Additional long-term data were published in October 2026 in The Laryngoscope, under the title DNA Immunotherapy (INO-3107) Long-Term Efficacy Supported by Enhanced Immunogenicity in HPV-6/11 RRP. The regulatory submission builds on earlier European development milestones, including Orphan Drug Designation granted by the European Commission in 2023 and Advanced Therapy Medicinal Product (ATMP) Certification from the EMA’s Committee for Advanced Therapies. The certification followed review of chemistry, manufacturing and controls (CMC) and nonclinical information. INOVIO stated that it prepared the application following pre-submission meetings with the EMA and its rapporteurs. The company’s CELLECTRA® delivery device also holds CE marking in the European Union, supporting commercialization of the device in the EU and other markets that recognize CE marking. These regulatory milestones reflect the company’s efforts to advance its DNA-based therapeutic platform through European regulatory pathways.
DNA Immunotherapy Targets HPV-6 and HPV-11
VOCERYQ is a plasmid DNA-based immunotherapy designed to generate an immune response against HPV-6 and HPV-11, the viral types primarily associated with recurrent respiratory papillomatosis. The disease is characterized by recurrent benign papillomas that develop in the respiratory tract, potentially causing airway obstruction, breathing complications, and significant voice impairment. Although the growths are generally non-cancerous, repeated recurrence can require frequent surgical removal, exposing patients to risks associated with repeated procedures, including potential damage to the vocal cords. VOCERYQ is designed to address the underlying HPV-associated disease mechanism and reduce the need for repeated surgical interventions. Treatment involves an initial standard-of-care surgical debulking of visible papillomas before the start of the nine-week dosing regimen, with administration supported by INOVIO’s proprietary CELLECTRA® 5PSP electroporation delivery device. The investigational approach aims to provide a treatment option that could reduce the frequency of surgical papilloma excisions and lessen the burden of recurrent procedures for eligible adult patients.
FDA Accelerated Approval Strengthens Regulatory Momentum
The FDA granted accelerated approval to VOCERYQ on October 30, 2026, for adults with RRP to reduce the frequency of surgical papilloma excisions. Continued approval remains contingent upon verification and description of clinical benefit through confirmatory studies. INOVIO expects the treatment to become available for ordering and shipment in the United States approximately 60 days after approval, with a full commercial launch anticipated in the first quarter of 2027. The company estimates that at least 25,000 patients in the United States are living with RRP, with additional diagnoses occurring each year. The EMA application represents another important step toward potential European availability of the therapy. If authorized, VOCERYQ could offer patients a new therapeutic approach to managing recurrent papillomas and reducing dependence on repeated surgical procedures. The regulatory review will determine whether the submitted evidence supports conditional marketing authorization in Europe, while further clinical evidence will remain important in establishing the treatment’s long-term benefits and role in RRP management.
Source: INOVIO press release



